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abstRact
IntroductIon: Since the introduction of the quadrivalent 
human papillomavirus vaccine, young girls and women have 
reported a broad range of symptoms. These have been de­
scribed as possible adverse effects of the vaccine. In this 
study, we describe demographic characteristics, symptom­
atology, clinical and laboratory test results in patients re­
ferred with suspected adverse effects in the Region of 
Southern Denmark.
Methods: We conducted a retrospective, descriptive 
study. The patients filled out a questionnaire, were inter­
viewed by a doctor and received a standard physical exam­
in ation and laboratory tests.
results: The study comprised 200 patients. The median 
age at referral was 22 (interquartile range (IQR): 19.5­26) 
years, and age at first vaccination was 14 (IQR: 12­21) years. 
The most common symptoms were headache (93%), fa­
tigue/tiredness (93%) and dizziness when standing up 
(90%). The median number of symptoms in each patient 
was 15. Five patients (2.5%) were diagnosed with postural 
orthostatic tachycardia syndrome (POTS). Of all patients, 
183 (91.5%) were terminated without a somatic diagnosis, 
one patient (0.5%) was terminated with a functional dis­
order and 11 patients (5.5%) were still in diagnostic workup 
when the present study concluded.
conclusIons: The patients reported a wide range of symp­
toms. We found an overall low prevalence of POTS. It 
should be further investigated whether these patients 
might suffer from a functional disorder rather than from ad­
verse effects associated with the vaccine.
FundIng: none.
trIal regIstratIon: not relevant.
The quadrivalent vaccine against human papillomavirus 
(qHPV) protects against infections caused by HPV of 
types 6, 11, 16 and 18. Since 2009, the vaccine has been 
offered to girls aged 12 years as part of the Danish child­
hood vaccination programme [1]. For the time being, 
more than 500,000 Danish girls and women have been 
vaccinated against HPV [2].
HPV infections are prevalent in the Danish popula­
tion, causing condyloma and cervical, oropharyngeal, 
anal, penile and vulvovaginal cancer [1]. In Denmark,  
approximately 375 women are diagnosed with cervical 
cancer, and 100 women die from this disease annually 
[2]. Studies have demonstrated a significantly lower risk 
of developing cervical dysplasia in women who were in­
oculated against HPV compared with unvaccinated 
women [3, 4]. Furthermore, the incidence of condyloma 
has been significantly reduced since the implementation 
of qHPV in Denmark [5].
Since the release of the vaccine, young girls and 
women have turned up with a variety of symptoms sus­
pected to be adverse effects of qHPV. These possible ad­
verse effects have received substantial publicity in the 
media. In 2015 and 2016, the number of Danish girls 
who were vaccinated against HPV was reduced markedly 
from > 90% to 23% [6].
The HPV vaccine has a number of well­documented 
side effects. Still, large cohort studies have found no  
increased frequency of severe diseases (e.g. autoim­
mune, neurological and thromboembolic diseases) or 
less severe diseases like postural orthostatic tachycardia 
syndrome (POTS) or complex regional pain syndrome  
[7, 8].
Until June 30 2016, 0.4% of the total number of vac­
cinated women (2,241) had reported possible adverse 
effects of the vaccine to the authorities [9]. In 2009­
2012, the number of reported possible adverse effects 
compared with the number of sold vaccine doses was 
stable. In 2015, this ratio increased by factor 24 [10].
In order to standardize the examination and treat­
ment of patients, five centres throughout Denmark were 
established in March 2015. These centres are respons­
ible for referral regarding possible adverse effects of the 
HPV vaccine. In the Region of Southern Denmark, the 
Department of Infectious Diseases (DID) and the 
Department of Paediatrics (DP) at Odense University 
Hospital are responsible for these patients.
The aim of this study is to describe demographic 
characteristics, symptomatology and clinical and labora­
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tory test results among patients referred with possible 
adverse effects from qHPV vaccine in the Region of 
Southern Denmark.
mEthOds
study design and population
We conducted a retrospective, descriptive study of pa­
tients referred from general practitioners to the DID and 
the DP with possible adverse effects of qHPV vaccine 
during the period from March 2015 to October 2016. All 
patients had received at least one vaccine dose. The pa­
tients went through an interview with a doctor and un­
derwent a standard physical examination and laboratory 
tests. Additionally, they filled­in a questionnaire before 
or after the examination. If data from the questionnaire 
were missing, the questionnaires were still included.  
Patients were excluded from this study if they failed to 
show up for examination, or if the questionnaire was not 
returned.
data collection
Questionnaire: The questionnaire contained information 
about demographic characteristics, symptomatology  
after any dose of the vaccine, medical treatment, dietary 
supplements, alternative treatment and previous med­
ical history. The questionnaire was constructed when 
the centre was established based on the knowledge ob­
tained from former studies.
Laboratory tests: We used baseline laboratory tests 
and vital parameters from local guidelines. 
Conclusion of diagnostic workup: We categorized 
the patients’ cases according to whether they were ter­
minated with a diagnosis (other than the International 
Classification of Diseases, tenth version (ICD­10) diagno­
sis DT881: other complication to vaccination or immun­
ization, which was given if no somatic explanation was 
found) and if they were referred to other medical de­
partments.
The data were manually entered twice using 
Microsoft Excel.
Outcome definitions
Categorical data were dichotomous with the values of 
Yes or No. Some categories were classified into sub­
groups for a more accurate differentiation. Continuous 
data were collected with numerical values.
statistical analysis
Continuous variables are described by median and inter­
quartile range (IQR), and categorical variables are pre­
sented as percentage frequencies and compared using 
the chi­squared test. All statistical tests were two­tailed 
and the significance level was set to p < 0.05.
Stata version 14 (StataCorp LP, College Station, 
Texas, USA) was used for data analysis.
Ethical considerations
The Danish Data Protection Agency (16/30720) and the 
Danish Health Authority (3­3013­1850/1/) granted per­
mission to conduct the study.
Trial registration: not relevant.
REsUlts
In total, 289 patients were referred to the DID and the 
DP in the study period. Of those, 200 girls and women – 
170 from the DID and 30 from the DP – fulfilled the in­
clusion criteria.
tablE 1
Demographic characteristics of the 200 girls who were referred with possible adverse effects to the 
quadrivalent human papillomavirus vaccine in the Region of Southern Denmark from March 2015 to  
October 2016.
age, yrs,  
median (iQR) n/respondents (%)
Referral 22 (19.5­26) –
1st vaccination 14 (12­21) –
Vaccine doses 
1 – 200/200 (100) 
2 – 197/200 (99)
3 – 184/200 (92)  
Reported to be completely healthy before vaccination – 155/196 (79)
Seen by doctor elsewhere – 189/194 (97)
Hospitalization before or after vaccination – 142/195 (73)
Living situation
With parents –   84/193 (44)
Alone –   36/193 (19)
With room mate –   73/193 (38)
Patients able to go to school or work fulltime – 101/193 (52)
Smokers –   43/197 (22)
Drink > 7 U of alcohol per week –     0/197
Ever abused drugs –   13/196 (7)
Adverse effects reported to authorities –   72/196 (37)
Followed the Danish childhood vaccination programme – 195/196 (99)
Measles vaccinated – 183/188 (97)
Any other vaccinations –   66/195 (34)
Dispositions 
Epilepsy –   17/195 (9)
Heart diseases –   61/195 (31)
Coronary diseases –   41/194 (21)
Lung diseases –   54/195 (28)
Metabolic disorders –   33/194 (17)
Cancer – 113/194 (58)
Rheumatic diseases –   96/195 (49)
Allergies 
Medicine –   27/195 (14)
Food –   36/195 (18)
Pollen –   41/196 (21)
Animals –   24/195 (12)
IQR = interquartile range.
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The demographic characteristics are shown in table 
1. The median age at referral was 22 years (IQR: 19.5­
26.0), and the median age at time of first vaccination 
was 14 years (IQR: 12­21). All patients had at least re­
ceived the first dose of the vaccine.
The symptoms and different treatment options are 
presented in table 2. The five most common symptoms 
were headache (93%), fatigue/tiredness (93%), dizziness 
when standing up (90%), difficulties concentrating or 
loss of memory (83%) and nausea (79%).
The median number of reported symptoms from 
each patient was 15 (range: 3­26). Furthermore, 103 
(52%) patients reported additional symptoms. Of these 
patients, 98 (95%) were from the DID and five (5%) from 
the DP. 
Time elapsed between any dose of vaccination and 
symptom onset was typically less than one month (49%). 
Of all patients, 28% reported symptom onset 2­6 
months after vaccination, and 23% of the patients re­
ported that the symptoms presented more than six 
months after any dose of vaccination. When we strat­
ified the population by time of vaccination (before or  
after six months), we found no difference between on­
set of headache (p = 0.39), fatigue/tiredness (p = 0.40), 
dizziness when standing up (p = 0.10), difficulties con­
centrating or loss of memory (p = 0.82) and nausea  
(p = 0.71).
Of all patients, 67% were using dietary supple­
ments, and 56% had tried one or more alternative treat­
ment methods. We found a significant difference be­
tween physical activity level before and after any dose 
of vaccination (p = 0.01) (Table 2).
In most patients, vital parameters and laboratory 
test results were within the normal range (table 3). Of 
76 patients who were tested at the DID for POTS, eight 
(11%) had a positive stand test and were referred to the 
Department of Cardiology for further examination. Five 
(2.5%) obtained a confirmed POTS diagnosis (ICD­10­
DI471J) by the cardiologists (table 4).
Table 4 is a summary of the results of the diagnostic 
workup and the specialized departments used to obtain 
a definite diagnosis. At the DID and the DP, 183 (91.5%) 
patients were terminated with the diagnosis DT881.
discUssiOn
In our study, the most commonly reported symptoms 
differed from those reported in other international  
studies. A cohort study from Slovenia describing adverse 
events following immunization with qHPV vaccine re­
ported that the most common symptoms were malaise, 
headache and fever [11]. An American study reported 
that the most frequent symptoms were syncope, local­
site reactions, dizziness, nausea, headache, hypersensi­
tivity reactions and urticariae according to the Vaccine 
Adverse Event Reporting System [12], while musculo­
skeletal pain, fatigue and headache were reported as 
the most prominent symptoms in a questionnaire­based 
American study of HPV vaccination symptomatology 
[13]. 
Because the subject of this study remains highly un­
explored, it was quite difficult to find comparable  
studies to include in the discussion. 
The frequency of the most commonly reported 
symptoms differed as well. In our study, headache was 
the most frequently reported symptom. In contrast to 
this, 57% of the patients in the American study reported 
tablE 2
Frequency of the most common symptomsa and management in 200 girls referred with possible adverse 
effects to the quadrivalent human papillomavirus vaccine in the Region of Southern Denmark from 
March 2015 to October 2016. The values are n/respondents (%).
Most commonly presenting complaints
Headache 186/200 (93)
Fatigue/tiredness 185/200 (93)
Dizziness when standing in upright position 180/200 (90)
Difficulty thinking or remembering 166/200 (83)
Nausea 158/200 (79)
≥ 1 other symptoms added in the free text section
All patients 103/200 (52)
Department of Infectious Diseases   98/170 (58)
Department of Paediatrics     5/30 (17)
Time elapsed between any dose of HPV vaccination and symptom onset, mo.s
≤ 1   87/179 (49)
2­6   50/179 (28)
> 6   42/179 (23)
Power of symptoms at time of referral compared to debut of symptoms 
Decreased   88/195 (46)
Unchanged   81/195 (42)
Increased   24/195 (12)
Most commonly presenting medication at any time
Painkillers   38/191 (20)
Prevention   32/191 (17)
Anti­depressants   20/191 (10)
Asthma medication   16/191 (8)
Sleeping pills   11/191 (6)
Effect of medical treatment   45/166 (27)
Dietary supplements 127/189 (67)
Changes in diet   61/190 (32)
Alternative treatment 108/192 (56)
Activity level before vaccination
Low   18/197 (9)
Moderate   66/197 (34)
High 113/197 (57)
Activity level after vaccination
Low 121/193 (63)
Moderate   41/193 (21)
High   31/193 (16)
HPV = human papillomavirus. 
a) Median (range) number of symptoms reported from the 27 symptoms listed in the questionnaire: 15 
(3­26).
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headache; and in the Slovenian study, headache com­
prised 11.4% of all adverse events. In a Danish study by 
Brinth et al, headache was reported by 82% of the pa­
tients [14]. This is consistent with the results in our 
study.
The number of reported symptoms was remarkably 
different from that reported in the Slovenian study, 
where each patient only reported an average of two ad­
verse events compared with a median of 15 in our study. 
In general, our study and that of Brinth et al both re­
ported various symptoms, all with a high frequency 
when compared to the above­mentioned international 
studies.
In the present study, five patients (2.5%) had a con­
firmed POTS diagnosis. Brinth et al [14] reported that 21 
of 35 (60%) patients fulfilled the criteria for POTS. The 
variation in these results must be considered in relation 
to the different settings of the studies. Brinth et al con­
ducted a study of selected patients referred to a spe­
cialized syncope unit, and these patients were already 
suspected of having POTS. The prevalence of persons 
suffering from POTS in Denmark is uncertain, but is esti­
mated to be 0.2% of the total population [14, 15]. POTS 
most commonly presents between 15 and 25 years of 
age, which is the same age at which the girls in this 
study are presenting symptoms [16]. Still, the preva­
lence in this particular age group is unknown, but it may 
explain the higher incidence in this study compared with 
the general population. The European Medicines Agency 
(EMA) has concluded that the number of vaccinated girls 
who are diagnosed with POTS is comparable to the ex­
pected incidence of POTS in this age group. Finally, the 
tablE 3
The presenting clinical features and baseline laboratory tests in 200 girls referred with possible adverse 
effects to the quadrivalent human papillomavirus vaccine in the Region of Southern Denmark from 





Systolic blood pressure, mmHg – 20.5 (94­177) –
Diastolic blood pressure, mmHg – 76.5 (56­96) –
Heart rate, bpm – 69 (40­107) –
O2 saturation, % – 99 (95­100) –
Temperature, °C – 37.3 (35.5­37.7) –
Weight, kg – 64.25 (46.3­150) –
Height, cm – 167 (150­188) –
BMI, kg/m2 – 22.9 (16.9­51.3) –
Positive stand test at the DID – 8/76 (11)
Normal urine
Glucose – – 144/144 (100)
Ketone – – 143/144 (99)
Blood – – 116/145 (80)
Protein – – 130/144 (90)
Nitrite – – 140/144 (97)
Leucocytes – – 96/144 (67)
pH – 6 (5­8.5) –
Normal blood test
Ferritin, μg/l 15­200 – 135/156 (87)
Haemoglobin, mmol/l 7.3­9.5 – 162/171 (95)
Leucocytes, × 109/l 3.5­8.8 – 141/171 (82)
Reticulocytes, × 109/l 31­97 – 144/154 (94)
SR, mm 2­30 – 159/163 (98)
Thrombocytes, × 109/l 165­400 – 165/171 (96)
Neutrofilocytes, × 109/l 1.5­7.5 – 163/170 (96)
Lymphocytes, × 109/l 1­4 – 167/169 (99)
Monocytes, × 109/l 0.2­0.8 – 159/169 (94)
Basofilocytes, × 109/l < 0.2 – 169/169 (100)
Eosinofilocytes, × 109/l < 0.5 – 163/169 (96)
Albumin, g/l 36­50 – 171/171 (100)
Potassium, mmol/l 3.5­4.4 – 166/171 (97)
Carbamide, mmol/l 2.6­6.4 – 153/167 (92)
Creatinine, μmol/l 45­90 – 170/172 (99)
eGFR, ml/min > 60 – 165/165 (100)
Sodium, mmol/l 137­145 – 164/170 (96)
Coagulation factor II + V, arbitrary U/l 0.7­1.3 – 143/167 (86)
ALT, U/l 10­45 – 158/172 (92)
Alkaline phosphatase, U/L 35­105 – 164/172 (95)
Bilirubin, μmol/l 5­25 – 150/169 (89)
LDH, U/L 105­205 – 130/167 (78)
HBA1c, mmol/mol < 48 – 157/158 (99)
TSH, × 10–3 IU/l 0.5­4.3 – 161/168 (96)
CRP, mg/l < 6 – 136/171 (80)
IgG, g/l 6.1­15.7 – 160/165 (97)
IgM, g/l 0.4­2.3 – 154/165 (93)
D­vitamin, nmol/l 50­160 – 131/162 (81)
P glucose – 5.5 (4.3­13) –
Normal ECG – 140/160 (88)
ALT = alanine transaminase; CRP = C­reactive protein; DID = Dept. of Infectious Diseases; ECG = elec­
trocardiography; eGFR = estimated glomerular filtration rate; HBA1c = glycated haemoglobin; LDH = 
lactate dehydrogenase; SR = sedimentation rate; TSH = thyroid­stimulating hormone.
tablE 4
Overview of definite diagnosis and specialized departments used to ob­
tain a definite diagnosis in the 200 girls referred with possible adverse ef­
fects to the quadrivalent human papillomavirus vaccine in the Region of 
Southern Denmark from March 2015 to October 2016.
n/respondents (%)
Terminated with DT881a 183/200 (91.5)
Terminated with DI471Jb     5/200 (2.5)
Terminated with 662039c     1/200 (0.5)
Still in diagnostic workup   11/200 (5.5)
Most common departments used for further diagnostic workup
Neurology   63/159 (40)
Cardiology   48/159 (30)
Rheumatology   29/159 (18)
Gastrointestinal system   27/159 (17)
Psychiatry   21/159 (13)
Headache clinic   19/159 (12)
a) Other complication to vaccination or immunization. 
b) Postural orthostatic tachycardia syndrome. 
c) Functional disorder.
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EMA has investigated the suspected association be­
tween POTS and qHPV vaccine and found none [8].
For the time being, there is no statistical evidence 
of a correlation between vaccination and onset of ad­
verse effects. Specifically, we found no significant differ­
ence between onset of the five most frequent symp­
toms and time of vaccination.
Despite the experienced severity and intensity of 
the patients’ symptoms, 91.5% of the patients were ter­
minated from the DID and the DP without a diagnosis. 
However, one patient from the DP was terminated with 
a functional disorder. A functional disorder is character­
ized by symptoms from one or more organ systems 
without a somatic explanation. Many people experience 
these symptoms every day without having a disease. If 
the symptoms become so severe and persistent that 
they affect the patients’ quality of life or ability to at­
tend school/work, a diagnosis of a functional disorder is 
established [17]. In the present study, we did find a de­
crease in the level of physical activity before and after 
vaccination, respectively. However, it is not possible for 
us to determine whether this change in physical activity 
was due to a physical or functional problem.
The study population was medically examined to 
clarify if there was any somatic explanation of their 
symptoms. The DP does have the expertise to diagnose 
functional disorders, and one patient was discharged 
with this diagnosis. The DID does not have the expertise 
to diagnose functional disorders. Instead, patients with 
no somatic diagnosis were referred to the Centre for 
Functional Disorders – unfortunately almost all patients 
declined. Yet, the symptomatology of this patient cohort 
is compatible with the symptomatology seen in func­
tional disorders. Patients with severe symptoms but no 
somatic diagnosis might try to explain their disease as 
adverse effects to qHPV vaccine.
The girls in this study frequently used dietary sup­
plements and alternative treatment methods. This  
underlines that the symptoms are experienced to be 
very problematic by the patients; and in despair due to 
the absence of any medical treatment, they try other 
methods.
A survey showed that the attendance to HPV vac­
cination in the childhood vaccination programme in 
Sweden is continuously high (80%). In Denmark, the at­
tendance has decreased remarkably from 90% to 27% 
since the precipitous rise of media attention following 
the documentary “The vaccinated girls” that was broad­
cast on national Danish television in 2015 [18]. This is 
consistent with a study from the Netherlands, which 
suggested that the media attention given to possible 
side effects to qHPV vaccine may explain the increased 
awareness hereof [19].
In our study, the young girls from the DP reported 
fewer symptoms than the older girls from the DID. This 
age­trend was also seen in a study from the Netherlands 
[19]. The reason for this age­trend is unknown, but it  
indicates that, regardless of their origin, the symptoms 
increase over time. A Japanese study showed that the 
symptomatology of adolescent females suffering from 
possible adverse effects of qHPV was significantly im­
proved by intervention [20]. Therefore, it might be im­
portant to investigate these patients at an early point  
in time to prevent the development of a more severe 
symptomatology. Despite that, the underlying cause re­
mains unknown; the patient cohort described in the pre­
sent study is presenting symptoms which must be sol­
emnly viewed. There are no doubt that we are facing a 
group of girls and women who are desperately seeking 
an explanation of their symptoms.
Our study has limitations. The main weakness is the 
descriptive nature of the study in a highly selected group 
of girls without any control group. Furthermore, the 
study is based on a questionnaire; hence most of the 
data are self­reported. The study is retrospective, which 
might lead to recall bias. It is reasonable to believe that 
the patients experiencing the most severe symptom­
atology are more likely to complete the questionnaire.  
It is also unknown whether the younger girls received 
help from their parents to fill out the questionnaire.  
The strength of this study is the possibility for the pa­
tients to add other symptoms than the ones provided in 
the questionnaire and to describe how the symptoms af­
fect their lives. The study comprised a considerable 
amount of information about symptomatology, demo­
graphic characteristics and an extended physical exam­
ination, which makes it possible to describe a large pa­
tient cohort.
cOnclUsiOns
The patients in our study reported a wide range of 
symptoms. The prevalence of POTS in this study was 
probably slightly higher than the anticipated prevalence 
in the background population. The symptomatology of 
the patients is compatible with the symptomatology 
seen in functional disorders. It may be important to in­
vestigate these patients at an early point to prevent the 
development of a more severe symptomatology. It 
should be further investigated whether these patients 
may suffer from a functional disorder rather than from 
adverse effects to the HPV vaccine.
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